Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism
| Autor: | André Lemay, Isabelle Cedrin, Catherine Mechain, Jocelyne Guy, Sylvie Dodin, Nacia Faure, Lucile Turcot-Lemay |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Ethinyl Estradiol-Norgestrel Combination Hirsutism medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Urology Ethinyl Estradiol Antiandrogen Drug Administration Schedule Contraceptives Oral Hormonal Flutamide chemistry.chemical_compound Endocrinology Oral administration Internal medicine medicine Humans Prospective Studies Gonadal Steroid Hormones hirsutism Chemotherapy Pregnancy business.industry Low dose Norgestrel Obstetrics and Gynecology Androgen Antagonists General Medicine Androgen medicine.disease Androgen receptor chemistry Drug Therapy Combination Female business Hormone |
| Zdroj: | Clinical Endocrinology. 43:575-582 |
| ISSN: | 1365-2265 0300-0664 |
| DOI: | 10.1111/j.1365-2265.1995.tb02922.x |
| Popis: | Summary BACKGROUND AND OBJECTIVE High doses of flutamide, which is the only antiandrogen that specifically blocks the androgen receptor, have recently been used with good clinical results in women with hirsutism. Since regression of hair growth requires long-term therapy, clinical and economic considerations are important. The use of the lowest efficacious dosage could reduce costs. This study was undertaken to compare safety and efficacy of a low dose of flutamide (125 mg twice daily) alone and in combination with a triphasic oral contraceptive (OC) in women with idiopathic hirsutism. PATIENTS Flutamide was administered orally in a low dose of 125mg twice daily for 12 months alone in women with no risk of pregnancy or during the use of an oral contraceptive. MEASUREMENTS Women were seen every 3 months and were evaluated for hirsutism score, hormone and lipid measurements. DESIGN The study, which was conducted as a prospective open trial, was proposed to patients with idiopathic hirsutism, that is, with serum androgen levels in normal range and LH/FSH ratio less than 2. RESULTS A statistically significant decrease in hirsutism score as compared to baseline was observed after only 3 months with either treatment, flutamlde alone (16.9 ± 1.6 vs 14.2 ± 1.7, P < 0.0001) or the combination of flutamide with OC (15.6 ± 0.8 vs 11.9 ± 0.8, P < 0.001). Three months after cessation of treatment a statistically significant decrease from baseline was observed in the two groups. Nevertheless, at 6 months post-treatment this decrease was still Significant only in the group who took flutamlde in Combination with an oral Contraceptive. Flutamide alone does not appear to modify the levels of lipoproteins. The association of flutamide with a triphasic formulation significantly Increased the HDL-C levels. CONCLUSIONS This study shows beneficial effects of a low dose of flutamide in women with idiopathic hirsutism. The addition of an oral contraceptive is judicious to prevent pregnancy and reduce recurrence of hirsutism after cessation of flutamide. Peripheral androgenic blockage does not modify lipid profiles and it might reduce the negative effect of oral contraceptive on HDL-C levels. The addition of electrolysis delays the recurrence of hirsutism after cessation of flutamide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text